Carla Boccaccio

List of Publications by Year
in descending order

49 papers	4,154 citations	182225 30 h-index	242451 47 g-index
50 all docs	50 docs citations	50 times ranked	7180 citing authors

#	Article	IF	Citations
1	METâˆ†14 promotes a ligand-dependent, AKT-driven invasive growth. Life Science Alliance, 2022, 5, e202201409.	1.3	7
2	Cancer of unknown primary stem-like cells model multi-organ metastasis and unveil liability to MEK inhibition. Nature Communications, 2021, 12, 2498.	5.8	20
3	ERBB3 overexpression due to miR-205 inactivation confers sensitivity to FGF, metabolic activation, and liability to ERBB3 targeting in glioblastoma. Cell Reports, 2021, 36, 109455.	2.9	18
4	ERBB3 as a therapeutic target in glioblastoma: overexpression can make the difference. Molecular and Cellular Oncology, 2021, 8, 1990677.	0.3	2
5	The Long-Lasting Protective Effect of HGF in Cardiomyoblasts Exposed to Doxorubicin Requires a Positive Feed-Forward Loop Mediated by Erk1,2-Timp1-Stat3. International Journal of Molecular Sciences, 2020, 21, 5258.	1.8	5
6	Colorectal cancer residual disease at maximal response to EGFR blockade displays a druggable Paneth cellâ€“like phenotype. Science Translational Medicine, 2020, 12, .	5.8	40
7	A simplified integrated molecular and immunohistochemistry-based algorithm allows high accuracy prediction of glioblastoma transcriptional subtypes. Laboratory Investigation, 2020, 100, 1330-1344.	1.7	12
8	Activation of the <scp>MET</scp> receptor attenuates doxorubicinâ€induced cardiotoxicity in vivo and in vitro. British Journal of Pharmacology, 2020, 177, 3107-3122.	2.7	20
9	Cerebrospinal fluid tumor DNA for liquid biopsy in glioma patientsâ€™ management: Close to the clinic?. Critical Reviews in Oncology/Hematology, 2020, 146, 102879.	2.0	17
10	Cancer of Unknown Primary (<scp>CUP</scp>): genetic evidence for a novel nosological entity? A case report. EMBO Molecular Medicine, 2020, 12, e11756.	3.3	10
11	â€œMetastatic Cancer of Unknown Primaryâ€•or â€œPrimary Metastatic Cancerâ€?. Frontiers in Oncology, 2019, 9, 1546.	1.3	35
12	Known and novel roles of the MET oncogene in cancer: a coherent approach to targeted therapy. Nature Reviews Cancer, 2018, 18, 341-358.	12.8	248
13	A Molecularly Annotated Model of Patient-Derived Colon Cancer Stemâ€“Like Cells to Assess Genetic and Nongenetic Mechanisms of Resistance to Anti-EGFR Therapy. Clinical Cancer Research, 2018, 24, 807-820.	3.2	23
14	Selective analysis of cancer-cell intrinsic transcriptional traits defines novel clinically relevant subtypes of colorectal cancer. Nature Communications, 2017, 8, 15107.	5.8	213
15	Genetic Evolution of Glioblastoma Stem-Like Cells From Primary to Recurrent Tumor. Stem Cells, 2017, 35, 2218-2228.	1.4	47
16	<scp>MET</scp> inhibition overcomes radiation resistance of glioblastoma stemâ€like cells. EMBO Molecular Medicine, 2016, 8, 550-568.	3.3	74
17	TNFâ€± promotes invasive growth through the MET signaling pathway. Molecular Oncology, 2015, 9, 377-388.	2.1	40
18	MET, a driver of invasive growth and cancer clonal evolution under therapeutic pressure. Current Opinion in Cell Biology, 2014, 31, 98-105.	2.6	35

#	Article	IF	Citations
19	MET Signaling in Colon Cancer Stem-like Cells Blunts the Therapeutic Response to EGFR Inhibitors. Cancer Research, 2014, 74, 1857-1869.	0.4	120
20	MET-Mediated Resistance to EGFR Inhibitors: An Old Liaison Rooted in Colorectal Cancer Stem Cells. Cancer Research, 2014, 74, 3647-3651.	0.4	30
21	The MET Oncogene in Glioblastoma Stem Cells: Implications as a Diagnostic Marker and a Therapeutic Target. Cancer Research, 2013, 73, 3193-3199.	0.4	56
22	Met signaling regulates growth, repopulating potential and basal cell-fate commitment of mammary luminal progenitors: implications for basal-like breast cancer. Oncogene, 2013, 32, 1428-1440.	2.6	53
23	The MET Oncogene as a Therapeutical Target in Cancer Invasive Growth. Frontiers in Pharmacology, 2012, 3, 164.	1.6	14
24	The MET Oncogene Is a Functional Marker of a Glioblastoma Stem Cell Subtype. Cancer Research, 2012, 72, 4537-4550.	0.4	120
25	Wild-type p53 controls cell motility and invasion by dual regulation of MET expression. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 14240-14245.	3.3	113
26	Induction of MET by Ionizing Radiation and Its Role in Radioresistance and Invasive Growth of Cancer. Journal of the National Cancer Institute, 2011, 103, 645-661.	3.0	300
27	Hepatocyte Growth Factor: A marker and a player in disseminated intravascular coagulation. Thrombosis Research, 2011, 127, 67-69.	0.8	15
28	Tumor cell-derived Timp-1 is necessary for maintaining metastasis-promoting Met-signaling via inhibition of Adam-10. Clinical and Experimental Metastasis, 2011, 28, 793-802.	1.7	49
29	A Disintegrin and Metalloproteinase-10 (ADAM-10) Mediates DN30 Antibody-induced Shedding of the Met Surface Receptor. Journal of Biological Chemistry, 2010, 285, 26335-26340.	1.6	61
30	Profiling YB-1 target genes uncovers a new mechanism for MET receptor regulation in normal and malignant human mammary cells. Oncogene, 2009, 28, 1421-1431.	2.6	81
31	Genetic Link Between Cancer and Thrombosis. Journal of Clinical Oncology, 2009, 27, 4827-4833.	0.8	63
32	Fibroblast nemosis arrests growth and induces differentiation of human leukemia cells. International Journal of Cancer, 2008, 122, 1243-1252.	2.3	28
33	Oncogenes, Cancer and Hemostasis. , 2007, , 1-15.		1
34	Scatter Factors in Tumor Progression. , 2006, , 111-142.		0
35	Invasive growth: a MET-driven genetic programme for cancer and stem cells. Nature Reviews Cancer, 2006, 6, 637-645.	12.8	492
36	Cancer and blood coagulation. Cellular and Molecular Life Sciences, 2006, 63, 1024-1027.	2.4	37

#	Article	IF	Citations
37	The MET oncogene drives a genetic programme linking cancer to haemostasis. Nature, 2005, 434, 396-400.	13.7	245
38	A Functional Role for Hemostasis in Early Cancer Development: Figure 1.. Cancer Research, 2005, 65, 8579-8582.	0.4	39
39	Interactions between growth factor receptors and adhesion molecules: breaking the rules. Current Opinion in Cell Biology, 2003, 15, 565-571.	2.6	240
40	A differentiation switch for genetically modified hepatocytes. FASEB Journal, 2002, 16, 1-18.	0.2	15
41	Scatter factors and invasive growth. Seminars in Cancer Biology, 2001, 11, 153-165.	4.3	112
42	Apoptosis Enhancement by the HIV-1 Nef Protein. Journal of Immunology, 2001, 166, 81-88.	0.4	91
43	Hepatocyte Growth Factor Is a Regulator of Monocyte-Macrophage Function. Journal of Immunology, 2001, 166, 1241-1247.	0.4	129
44	HGF/scatter factor selectively promotes cell invasion by increasing integrin avidity. FASEB Journal, 2000, 14, 1629-1640.	0.2	88
45	HGF/scatter factor selectively promotes cell invasion by increasing integrin avidity. FASEB Journal, 2000, 14, 1629-1640.	0.2	90
46	Plasminogen-Related Growth Factor and Semaphorin Receptors: A Gene Superfamily Controlling Invasive Growth. Experimental Cell Research, 1999, 253, 88-99.	1.2	61
47	Induction of epithelial tubules by growth factor HGF depends on the STAT pathway. Nature, 1998, 391, 285-288.	13.7	485
48	The HIV-1 Nef Protein Interferes with Phosphatidylinositol 3-Kinase Activation 1. Journal of Biological Chemistry, 1996, 271, 6590-6593.	1.6	55
49	Ligand-Independent Tyrosine Phosphorylation of the Receptor Encoded by thec-neuOncogene. Growth Factors, 1991, 5, 233-242.	0.5	5